VTYX VENTYX BIOSCIENCES INC

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

ENCINITAS, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:

  • Event: Cowen 43rd Annual Health Care Conference

    Location: Boston, MA

    Date: Wednesday, March 8, 2023
  • Event: Barclays Global Healthcare Conference

    Location: Miami, FL

    Date: Wednesday, March 15, 2023

    Time: 9:30-9:55 AM ET
  • Event: Jefferies Biotech on the Bay Summit

    Location: Miami, FL

    Date: Thursday, March 16, 2023

A webcast of the Barclays presentation will be available in the Investors and News section of the Ventyx website at . A webcast replay will also be available on this website shortly after conclusion of the event for thirty days.

About Ventyx Biosciences

Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes three internally discovered clinical programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in Encinitas, California. For more information about Ventyx, please visit .

Investor Relations Contact

Patti Bank

Managing Director

ICR Westwicke

(415) 513-1284



EN
28/02/2023

Underlying

VTYXVENTYX BIOSCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on VENTYX BIOSCIENCES INC

 PRESS RELEASE
Free
VTYX VENTYX BIOSCIEN...

Ventyx Provides Clinical and Corporate Updates

Ventyx Provides Clinical and Corporate Updates Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in preparation for the global Phase 3 development planInterim analysis for the ongoing Phase 2 recurrent pericarditis study to now be presented as part of Ventyx’s R&D Day planned for Q1 2026 SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stag...

December 2, 2025 1 EN
 PRESS RELEASE
Free
VTYX VENTYX BIOSCIEN...

Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Hea...

Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York. Piper Sandler 37th Annual Healthcare Conference details:Fireside C...

December 1, 2025 1 EN
 PRESS RELEASE
Free
VTYX VENTYX BIOSCIEN...

Ventyx Biosciences to Participate in the Jefferies Global Healthcare C...

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference in London SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference in London. Jefferies Global Healthcare Conference details:Fireside ChatDate: Wednesday,...

November 17, 2025 1 EN
 PRESS RELEASE
Free
VTYX VENTYX BIOSCIEN...

Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Hi...

Ventyx Biosciences Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Progress Data from the recent Phase 2 study position Ventyx’s NLRP3 inhibitor VTX3232 as a next generation, oral anti-inflammatory therapy, for cardiovascular disease Positive topline data from Phase 2a biomarker trial support the potential use of VTX3232 as a disease-modifying therapy for patients with Parkinson’s diseaseTopline data from Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025Cash, cash equivalents and marketable securities balance of $192.6M as of S...

November 6, 2025 1 EN
 PRESS RELEASE
Free
VTYX VENTYX BIOSCIEN...

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Stu...

Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors VTX3232 demonstrated significant reductions in cardiovascular risk factors, with additional benefits when combined with semaglutide VTX3232 monotherapy achieved ~80% reduction in hsCRP within the first weekVTX3232 monotherapy reduced IL-6 levels at Week 12 below the threshold for cardiovascular risk of ≤1.65ng/L1Statistically significant reductions in Lp(a) and liver inflammationNo effect on weight either as a monotherapy or as add-on to semagluti...

October 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch